Alembic Pharmaceuticals Limited
NSE: APLLTD BSE: APLLTD
NSE
764.55
-4.85 (-0.63%)
Prev Close
769.4
Open Price
768.8
Volume
22,821
Today Low / High
761.05 / 768.8
52 WK Low / High
725.2 / 1107.9
Range
726 - 803
BSE
762.55
-6.00 (-0.78%)
Prev Close
768.55001
Open Price
773.95001
Volume
745
Today Low / High
760.9 / 773.95001
52 WK Low / High
725.6 / 1107.8
Range
724 - 801
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 764.55 (target range: 726 - 803), reflecting a change of -4.85 (-0.63036%). On the BSE, it is listed at 762.55 (target range: 724 - 801), showing a change of -6.00001 (-0.78069%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
23 Jan
768.80
-0.55%
22 Jan
761.95
0.98%
21 Jan
762.45
-0.09%
20 Jan
769.90
-0.62%
19 Jan
771.00
-0.16%
16 Jan
793.00
-2.28%
14 Jan
795.00
-0.64%
13 Jan
804.70
-0.45%
12 Jan
800.00
-0.39%
09 Jan
815.80
-1.94%
08 Jan
825.00
-1.24%
07 Jan
825.70
-0.24%
06 Jan
838.00
-1.47%
05 Jan
841.75
-0.50%
02 Jan
835.00
0.01%
01 Jan
843.00
-0.63%
31 Dec
836.50
1.15%
30 Dec
838.05
-0.17%
29 Dec
851.90
-1.34%
26 Dec
863.20
-1.27%
Alembic Pharmaceuticals Limited Graph
Alembic Pharmaceuticals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Alembic Pharmaceuticals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 764.55, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 762.55 | 770.18 | 693.16 - 847.19 |
| 777.80 | 622.24 - 933.36 | ||
| 785.43 | 549.80 - 1,021.05 | ||
| Bearish Scenario | 762.55 | 754.92 | 679.43 - 830.42 |
| 747.30 | 597.84 - 896.76 | ||
| 739.67 | 517.77 - 961.58 |
Overview of Alembic Pharmaceuticals Limited
ISIN
INE901L01018
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
161,365
Market Cap
150,282,336,454
Last Dividend
11
Official Website
IPO Date
2011-09-20
DCF Diff
-169.40
DCF
934
Financial Ratios Every Investor Needs
Stock Dividend of APLLTD
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-07-29 | July 29, 25 | 11 | 11 | 2025-07-29 | 2025-08-07 | |
| 2024-07-15 | July 15, 24 | 11 | 11 | 2024-07-15 | 2024-08-21 | |
| 2023-07-28 | July 28, 23 | 8 | 8 | 2023-07-28 | 2023-09-03 | |
| 2022-08-17 | August 17, 22 | 10 | 10 | 2022-08-18 | 2022-09-03 | |
| 2021-07-19 | July 19, 21 | 14 | 14 | 2021-07-20 | 2021-07-31 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 6,672.07 Cr | 1,880.76 Cr | 4,791.31 Cr | 0.7181 | 521.91 Cr | 0.00 Cr | 2,701.75 Cr | 583.42 Cr | 29.68 | 989.11 Cr | 0.0874 |
| 2024-03-31 | 6,228.63 Cr | 1,796.12 Cr | 4,432.51 Cr | 0.7116 | 474.92 Cr | 0.00 Cr | 2,508.44 Cr | 615.82 Cr | 31.33 | 914.08 Cr | 0.0989 |
| 2023-03-31 | 5,652.62 Cr | 1,774.78 Cr | 3,877.84 Cr | 0.6860 | 721.84 Cr | 0.00 Cr | 1,980.52 Cr | 341.99 Cr | 17.40 | 696.16 Cr | 0.0605 |
| 2022-03-31 | 5,305.79 Cr | 1,498.21 Cr | 3,807.58 Cr | 0.7176 | 838.46 Cr | 0.00 Cr | 1,830.88 Cr | 520.94 Cr | 26.50 | 858.50 Cr | 0.0982 |
| 2021-03-31 | 5,393.13 Cr | 1,340.21 Cr | 4,052.92 Cr | 0.7515 | 670.00 Cr | 0.00 Cr | 2,331.56 Cr | 1,146.50 Cr | 59.18 | 1,466.31 Cr | 0.2126 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 90.10 Cr | 7,772.94 Cr | 2,583.42 Cr | 5,190.9400 Cr | 1,257.50 Cr | 1,167.40 Cr | 2,288.14 Cr | 3,360.76 Cr | 0.00 Cr | 0.00 Cr | 127.21 Cr | 2,412.3300 Cr |
| 2024-03-31 | 120.21 Cr | 6,445.58 Cr | 1,627.38 Cr | 4,818.2000 Cr | 513.16 Cr | 392.95 Cr | 1,643.54 Cr | 3,071.05 Cr | 0.00 Cr | -131.28 Cr | 93.02 Cr | 1,455.0000 Cr |
| 2023-03-31 | 75.48 Cr | 6,182.83 Cr | 1,812.36 Cr | 4,370.4700 Cr | 722.02 Cr | 646.54 Cr | 1,475.27 Cr | 2,999.73 Cr | 218.79 Cr | -83.14 Cr | 96.33 Cr | 1,636.9300 Cr |
| 2022-03-31 | 61.09 Cr | 7,122.03 Cr | 1,884.48 Cr | 5,237.5500 Cr | 717.11 Cr | 656.02 Cr | 1,609.70 Cr | 3,947.26 Cr | 69.22 Cr | -197.69 Cr | 118.40 Cr | 1,716.5300 Cr |
| 2021-03-31 | 98.06 Cr | 6,708.98 Cr | 1,642.01 Cr | 5,066.9600 Cr | 583.61 Cr | 485.55 Cr | 1,486.15 Cr | 3,648.03 Cr | 299.87 Cr | 85.52 Cr | 49.31 Cr | 1,280.8400 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 87.9700 Cr | -568.4100 Cr | 443.7100 Cr | -475.6500 Cr | -36.7300 Cr | 83.4800 Cr | -563.6200 Cr | 583.4200 Cr | 765.1200 Cr | -216.2200 Cr | -644.6000 Cr |
| 2024-03-31 | 803.2000 Cr | -320.6100 Cr | -437.8700 Cr | 475.7300 Cr | 44.7300 Cr | 120.2100 Cr | -327.4700 Cr | 615.8200 Cr | -205.4100 Cr | -157.2500 Cr | -168.2800 Cr |
| 2023-03-31 | 723.9500 Cr | -447.5900 Cr | -261.9600 Cr | 280.5400 Cr | 14.3900 Cr | 75.4800 Cr | -443.4100 Cr | 354.5900 Cr | 5.8700 Cr | -196.5600 Cr | 134.4400 Cr |
| 2022-03-31 | 552.3500 Cr | -371.9700 Cr | -217.3500 Cr | 126.7100 Cr | -36.9700 Cr | 61.0900 Cr | -425.6400 Cr | 620.1100 Cr | 129.9800 Cr | -275.1900 Cr | -123.5500 Cr |
| 2021-03-31 | 1,463.3800 Cr | -838.8100 Cr | -597.4300 Cr | 803.8700 Cr | 26.2200 Cr | 98.0600 Cr | -659.5100 Cr | 1,368.0800 Cr | -1,239.7500 Cr | 0.0000 Cr | -298.6200 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 1,910.15 Cr | 1,029.53 Cr | 880.62 Cr | 0.4610 | 239.62 Cr | 184.71 Cr | 9.40 | 322.60 Cr | 0.0967 |
| 2025-06-30 | 1,710.72 Cr | 407.41 Cr | 1,303.31 Cr | 0.7618 | 880.54 Cr | 154.38 Cr | 7.85 | 272.41 Cr | 0.0902 |
| 2025-03-31 | 1,769.62 Cr | 618.02 Cr | 1,151.60 Cr | 0.6508 | 230.79 Cr | 156.89 Cr | 7.98 | 267.89 Cr | 0.0887 |
| 2024-12-31 | 1,692.75 Cr | 439.54 Cr | 1,253.21 Cr | 0.7403 | 855.69 Cr | 138.42 Cr | 7.01 | 253.53 Cr | 0.0818 |
| 2024-09-30 | 1,647.98 Cr | 429.12 Cr | 1,218.86 Cr | 0.7396 | 827.39 Cr | 153.41 Cr | 7.79 | 238.53 Cr | 0.0931 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 143.03 Cr | 12.15 Cr | 155.18 Cr | 1,313.93 Cr | 2,540.70 Cr | 4,349.68 Cr | 3,514.73 Cr | 8,396.93 Cr | 3,080.91 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 83.48 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -5,189.52 Cr |
| 2025-03-31 | 90.10 Cr | 0.00 Cr | 90.10 Cr | 1,399.79 Cr | 2,288.14 Cr | 4,087.80 Cr | 3,360.76 Cr | 7,772.94 Cr | 2,583.42 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 128.95 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -4,887.64 Cr |
| 2024-09-30 | 122.05 Cr | 27.22 Cr | 149.27 Cr | 1,267.68 Cr | 2,012.52 Cr | 3,762.39 Cr | 3,124.86 Cr | 7,230.25 Cr | 2,342.61 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 154.38 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 156.89 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 138.42 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 153.41 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 134.71 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,631.90 | ₹3,915,474,737,543.00 | ₹1,678,650.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,011.50 | ₹1,595,864,368,670.00 | ₹460,453.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,932.20 | ₹1,330,835,159,168.00 | ₹315,832.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,235.60 | ₹1,028,677,688,308.00 | ₹3,888,844.00 |
| Lupin Limited | LUPIN | ₹2,137.20 | ₹976,270,408,183.00 | ₹578,346.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹882.00 | ₹887,498,379,180.00 | ₹460,318.00 |
| Mankind Pharma Limited | MANKIND | ₹2,107.60 | ₹870,027,969,747.00 | ₹406,697.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,750.50 | ₹687,558,532,500.00 | ₹77,302.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,132.50 | ₹657,757,838,048.00 | ₹511,822.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,967.70 | ₹555,286,531,869.00 | ₹424,174.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,016.40 | ₹548,710,229,945.00 | ₹4,200,664.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,462.80 | ₹371,118,530,090.00 | ₹47,635.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,699.60 | ₹337,276,210,550.00 | ₹73,196.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,530.80 | ₹290,197,644,232.00 | ₹138,093.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,846.00 | ₹289,177,746,000.00 | ₹132,465.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,351.60 | ₹219,624,415,620.00 | ₹259,357.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,319.00 | ₹207,975,000,000.00 | ₹5,165.00 |
| Eris Lifesciences Limited | ERIS | ₹1,385.60 | ₹188,742,124,170.00 | ₹94,274.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,251.00 | ₹170,008,859,139.00 | ₹26,149.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹956.10 | ₹151,417,316,063.00 | ₹139,597.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹764.55 | ₹150,282,336,454.00 | ₹22,821.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹831.95 | ₹149,010,456,347.00 | ₹318,008.00 |
| Cohance Lifesciences Limited | COHANCE | ₹381.60 | ₹145,987,620,624.00 | ₹380,203.00 |
| Granules India Limited | GRANULES | ₹565.00 | ₹137,107,824,540.00 | ₹972,146.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,723.00 | ₹130,968,152,208.00 | ₹65,701.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹883.50 | ₹108,388,970,958.00 | ₹208,914.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,395.50 | ₹89,561,965,581.00 | ₹32,077.00 |
| Strides Pharma Science Limited | STAR | ₹796.25 | ₹73,392,523,523.00 | ₹356,395.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹768.70 | ₹69,680,574,898.00 | ₹277,301.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹424.80 | ₹65,037,754,238.00 | ₹81,217.00 |
| FDC Limited | FDC | ₹369.60 | ₹60,174,607,046.00 | ₹49,065.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹267.00 | ₹52,220,344,872.00 | ₹242,372.00 |
| Sequent Scientific Limited | SEQUENT | ₹201.37 | ₹50,307,022,432.00 | ₹364,240.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.94 | ₹40,545,727,205.00 | ₹476,606.00 |
| Innova Captab Limited | INNOVACAP | ₹678.05 | ₹38,801,363,108.00 | ₹1,793,841.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,135.70 | ₹35,322,374,336.00 | ₹4,017.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹688.40 | ₹34,915,031,882.00 | ₹42,892.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹317.80 | ₹34,629,161,217.00 | ₹174,725.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹370.05 | ₹33,774,463,500.00 | ₹102,103.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹309.70 | ₹31,057,492,108.00 | ₹32,969.00 |
| Suven Life Sciences Limited | SUVEN | ₹134.07 | ₹30,497,439,180.00 | ₹248,500.00 |
Key Executives
Chief Scientific Officer
J. Venkat Raman S.
Gender: Not Specified
Year Born: 1958
Senior Vice President of SCM & Operations
Sachin Ghosalkar
Gender: Not Specified
Year Born:
Head-Legal & Taxation
Amresh Choudhary
Gender: male
Year Born:
Executive Chairman & Chief Executive Officer
Chirayu Ramanbha Amin
Gender: male
Year Born: 1946
Chief Financial Officer
G. Krishnan
Gender: male
Year Born:
MD & Executive Director
Pranav Chirayu Amin
Gender: male
Year Born: 1975
MD & Executive Director
Shaunak Chirayu Amin
Gender: male
Year Born: 1978
Executive Director
Raj Kumar Shreeram Baheti
Gender: male
Year Born: 1959
Chief Business Development Officer
Udit C. Amin
Gender: male
Year Born: 1980
Company Secretary & Compliance Officer
Manisha Saraf
Gender: female
Year Born:
FAQs about Alembic Pharmaceuticals Limited
Who is the CEO of the company?
The CEO is Chirayu Ramanbhai Amin.
What is the current market price of the stock?
The current price is ₹764.55.
What is the 52-week price range?
The range is ₹725.2-1107.9.
What is the market capitalization of the company?
The market capitalization is ₹15,028.23 crores.
What is the dividend yield?
The dividend yield is 1.44%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 23.69.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Alembic Pharmaceuticals Limited (ISIN: INE901L01018) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹15,028.23 crores and an average daily volume of 161,365 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹11.